

International Journal of Medical Sciences

2024; 21(12): 2244-2251. doi: 10.7150/ijms.97654

**Research Paper** 

# Herpes Zoster Risk After Total Knee Replacement: a multicenter, propensity-score-matched cohort study in the United States

Wen-Chieh Liao, PhD<sup>1,2</sup>, Shao-Wei Lo, MD<sup>3</sup>, Chih-Lung Wu, MD, PhD<sup>4,5</sup>, Sin-Ei Juang, MD, PhD<sup>6</sup>, Hui-Chin Chang, MLS<sup>5,7,8</sup>, Shuo-Yan Gau, MD, FRSPH<sup>10,11,12</sup>, Chen-Pi Li, MS<sup>9</sup>⊠

- 1. Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- 2. Doctoral Program in Tissue Engineering and Regenerative Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- 3. Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- 4. Department of Orthopedic Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.
- 5. School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- 6. Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- 7. Evidence-based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
- 8. Library, Chung Shan Medical University Hospital, Taichung, Taiwan.
- 9. Department of Nursing & Tungs' Taichung MetroHarbor Hospital, Taiwan.
- 10. Department and Graduate Institute of Business Administration, National Taiwan University, Taipei, Taiwan.
- 11. Department of Pharmacology, Chung Shan Medical University, Taichung, Taiwan.
- 12. Orthopedics Department, Chi-Mei Medical Center, Tainan, Taiwan.

Corresponding author: Chen-Pi Li, MS, Department of Nursing & Tungs' Taichung MetroHarbor Hospital, Taiwan; No. 699, Section 8, Taiwan Boulevard, Wuqi District, Taichung City 43503 Taiwan. Email: g971107@yahoo.com.tw.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

#### Received: 2024.04.23; Accepted: 2024.08.09; Published: 2024.08.19

#### Abstract

**Background:** Total knee replacement (TKR) is a common surgical procedure for osteoarthritis (OA) patients. TKR may increase susceptibility to herpes zoster (HZ) by inducing immunosuppression, surgical stress, and nerve injury. However, limited data exist on the relationship between TKR and HZ. This study examined the risk of HZ over time among OA patients who underwent TKR and those who did not, using a large population-based cohort.

**Method:** Utilizing the TriNetX research network, people with OA and underwent TKR were recruited as case group. After 1:1 propensity score matching, OA patients who never experienced TKR were included as control group. Covariates, including demographics, comorbidities, and laboratory data, were balanced using propensity score matching. A 5-year follow-up assessed the hazard ratio of incident HZ and related complications.

**Results:** Compared to the control group, a significantly elevated risk of HZ was observed in the TKR cohort across 5-year follow-up period, with the hazard ratio of 1.223 (95% CI: 1.089-1.373). Zoster without complications presented 1.173-fold risk in TKR patients while comparing with non-TKR controls. However, most other secondary outcomes related to HZ complications—such as encephalitis, neurological involvement, ocular disease, and disseminated zoster—did not show a significant increase in risk. The risk of HZ was statistically significant for females and older adults in the TKR cohort than in the control cohort.

**Conclusions:** OA patients who underwent TKR had an increased risk of HZ compared to those who did not receive the procedure, especially females and older adults. These findings highlight the need for HZ monitoring/prevention protocols and further research on mitigating viral reactivation after major joint surgery.

Keywords: osteoarthritis; total knee replacement; herpes zoster, risk; cohort study; electronic medical records

# Introduction

Herpes zoster (HZ), a painful and debilitating neurological syndrome commonly referred to as shingles, arises from the reactivation of the varicella-zoster virus (VZV)[1]. HZ affects approximately 1 in 3 people during their lifetime[2]. The risk of developing HZ increases sharply after 50

years of age[3]. Once reactivated, the virus causes a localized, painful skin rash and blisters along dermatomal distributions[4]. HZ is associated with several acute and chronic complications, including postherpetic neuralgia, vision loss, neurological injuries, and secondary bacterial infections[5, 6]. Given this considerable disease burden, identifying and mitigating risk factors for HZ reactivation are crucial public health priorities.

The reactivation of VZV can be either spontaneous (70% of cases) or provoked (30% of cases) by factors that impair cellular immunity, such as cancer, HIV, steroid intake, diabetes, and tuberculosis[6, 7]. Emerging evidence indicates certain surgical procedures, such as dental, facial, skull, and video-assisted thoracic surgeries, may increase susceptibility to HZ postoperatively[8-10]. Total knee replacement (TKR) is a common orthopedic surgery that involves replacing the damaged knee joint with an artificial one. TKR is performed to restore the mobility and comfort in patients with severe osteoarthritis (OA)[11]. In the US alone, more than 600,000 TKR procedures are done every year[12]. However, there is a possibility that TKR may increase the risk of HZ, as suggested by a few case reports[13, 14]. Wei et. al. reported an 88-year-old woman who developed HZ on the right knee and above, three weeks after TKR[13]. Jain et. al. reported a 67-year-old woman who developed HZ in the L2-3 dermatomal area, four weeks after TKR[14]. Despite these anecdotal case reports, no large-scale studies have systematically examined the relationship between TKR and HZ.

In this study, we aimed to address this critical evidence gap by examining the association between TKR and subsequent HZ risk using a robust matched cohort design. Our goal was to determine if TKR impacts HZ risk, facilitating enhanced prevention, monitoring, and treatment strategies in this large and growing population of TKR recipients.

# Methods and Materials

# Study population

This study was performed in a retrospective cohort design. The TriNetX research network and its subset, the US collaborative network, was utilized. TriNetX research networks provide users de-identified electronic medical records from their health collaborative organizations (HCOs) for analytical purposes. This global-federated research network contains more than 120 HCOs in the system and had been utilized in large-scale studies delivering outcome evaluation[15-18]. In the main analysis, we utilized the US collaborative network, a subset containing more than 59 HCOs solely in the United States. This study adhered to the STROBE guideline and the need of ethical approval was exempted by the Institutional Review Board of Tungs' Taichung MetroHarbor Hospital (IRB TTMHH No.: 112207N).

# Settings and outcome evaluation

Enrollment of participants spanned by January 1st, 2005 to December 31st, 2017. All participants had a follow-up time for greater than 5 years. People with visiting record in the TriNetX system and was diagnosed of OA were included as study population in this study. All individuals less than 18-year-old, having previous cancer record and having previous herpes zoster history were excluded from further analyses. People with OA and underwent TKR within the enrollment period were recruited as the TKR cohort. To determine non-TKR control cohort, people with OA and never underwent TKR surgery were included. In the main analysis, propensity score matching was performed based on 1:1 ratio and matching covariates included potential confounders including age, sex, socioeconomic statuses, medical utilization status and comorbidities. Primary outcome was set as incident herpes zoster. Secondary outcome was set as subgroups of herpes zoster, including zoster encephalitis, zoster with other nervous systemic involvement, zoster ocular disease, disseminated zoster, zoster with other complications and zoster without complications. Information of the applied algorithms of study population, covariates and outcomes were reported in Table S1. To validate the results, sensitivity analyses based on different matching covariates, wash-out periods and follow-up periods and stratification analyses based on variation on age and sex subgroups were performed. For sensitivity analyses based on different matching covariates, 3 different models were applied as the following design. Model 1: propensity score matching performed on age at index, sex, race and comorbidities. Model 2: propensity score matching performed on age at index, sex, race, body mass index, lab data, status of comorbidities, lifestyle, socioeconomic issues, medical utilization status, vaccination for herpes zoster status and comedication status. Model 3: propensity score matching performed on age at index, sex, race, body mass index, lab data, status of comorbidities, lifestyle, socioeconomic issues, medical utilization status, vaccination for herpes zoster status in different definition (Zostavax® Merck, Shingrix GSK.; CPT code: 90736, 90750). For sensitivity analyses based on different wash-out periods, incident herpes zoster occurred within the period were not calculated as outcome events. In the respective 3 models, 12 months, 24 months and 36

months, were respectively applied as wash-out periods to address potential reversed causation bias. For sensitivity analyses based on different follow-up period, the follow-up-period of 8 years, 10 years and 15 years were applied.

## Statistical analyses

The TriNetX platform's analytical instruments were employed to conduct the data analysis. Difference in baseline characteristics were evaluated using standardized difference (SD). A SD value exceeding 0.1 was deemed to have significant difference. The likelihood of future herpes zoster development was assessed by calculating hazard ratios. To ascertain statistical relevance, 95% confidence intervals were determined in conjunction with the hazard ratios.

# Results

#### Baseline characteristics of the study subjects

We analyzed the data from 43,670 OA patients who underwent TKR and an equal number of patients who never received the procedure (**Figure 1**). The demographic characteristics, comorbidities, and laboratory data of the two cohorts before and after propensity score matching are presented in **Table 1**. The TKR and control cohorts had similar age, sex, race, lifestyle, comorbidities, socioeconomic status, comedication status, medical utilization status, vaccination status, and laboratory data after matching, indicating a good balance between the groups (Standardized difference < 0.1). The mean age of the matched participants was  $64.3\pm10.4$  years for the TKR cohort and  $64.3\pm10.8$  years for the control cohort. Approximately 60% of the patients in both cohorts were women. The majority of the patients were Caucasian (71.8% vs. 71.9% in TKR and control cohort, respectively).

# Risk of herpes zoster after total knee replacement

The risk of HZ was assessed in both TKR and control cohorts. Compared to the control group, a significantly elevated risk of HZ was observed in the TKR cohort across 5-year follow-up period, with the hazard ratio of 1.223 (95% CI: 1.089-1.373) (Figure 2). Zoster without complications presented 1.173-fold risk in TKR patients while comparing with non-TKR controls. However, most other secondary outcomes of herpes zoster did not present significance in future risk (Figure 3). The findings in HZ risk remained consistent across different covariate-matching models, wash-out periods and longer follow-up periods (Table S2).



Figure 1. Patient selection process.

#### Table 1. Baseline characteristics of study subjects (before and after propensity score matching)

	Before matching			After matching <sup>a</sup>		
	TKR cohort (n = 43,670)	Control cohort $(n = 2,073,676)$	Standardized difference	TKR cohort (n = 43,670)	Control cohort (n=43,670)	Standardized difference
Age at index	,	· · · · · · · · · · · · · · · · · · ·		. ,		
Mean±SD	$64.3 \pm 10.4$	$60.6 \pm 14.6$	0.29	$64.3 \pm 10.4$	$64.3 \pm 10.8$	0.01
Sex						
Male	16851 (38.6)	805087 (38.8)	0.00	16851 (38.6)	16914 (38.7)	0.00
Female	26723 (61.2)	1213427 (58.5)	0.05	26723 (61.2)	26662 (61.1)	0.00
Race, n (%)	· · /				× /	
White	31364 (71.8)	1404380 (67.7)	0.09	31364 (71.8)	31389 (71.9)	0.00
Black or African American	4741 (10.9)	259381 (12.5)	0.05	4741 (10.9)	4719 (10.8)	0.00
Asian	1267 (2.9)	45289 (2.2)	0.05	1267 (2.9)	1267 (2.9)	0.00
Native Hawaiian or other Pacific Islander	388 (0.9)	7665 (0.4)	0.07	388 (0.9)	404 (0.9)	0.00
Lifestyle						
Alcohol dependence, smoking and substance use	2392 (5.5)	128739 (6.2)	0.03	2392 (5.5)	2179 (5.0)	0.02
Comorbidities						
Hypertension	12263 (28.1)	456075 (22.0)	0.14	12263 (28.1)	12052 (27.6)	0.01
Diabetes mellitus	4506 (10.3)	197939 (9.5)	0.03	4506 (10.3)	4406 (10.1)	0.01
Hyperlipidemia	7098 (16.3)	267686 (12.9)	0.09	7098 (16.3)	6908 (15.8)	0.01
Ischemic heart diseases	3104 (7.1)	122550 (5.9)	0.05	3104 (7.1)	2901 (6.6)	0.02
Chronic kidney disease	1120 (2.6)	54785 (2.6)	0.00	1120 (2.6)	923 (2.1)	0.03
Chronic obstructive pulmonary disease	1163 (2.7)	56763 (2.7)	0.00	1163 (2.7)	991 (2.3)	0.03
Ankylosing spondylitis	52 (0.1)	2191 (0.1)	0.00	52 (0.1)	27 (0.1)	0.02
Systemic lupus erythematosus	158 (0.4)	9752 (0.5)	0.02	158 (0.4)	92 (0.2)	0.03
Sjögren syndrome	133 (0.3)	6284 (0.3)	0.00	133 (0.3)	86 (0.2)	0.02
Psoriasis	302 (0.7)	14742 (0.7)	0.00	302 (0.7)	218 (0.5)	0.03
Socioeconomic Status						
Health hazards related to socioeconomic and	214 (0.5)	14202 (0.7)	0.03	214 (0.5)	147 (0.3)	0.02
psychosocial circumstances						
Medical Utilization Status						
Ambulatory visit	27839 (63.7)	1128558 (54.4)	0.19	27839 (63.7)	27711 (63.5)	0.01
Inpatient visit	10930 (25.0)	288753 (13.9)	0.28	10930 (25.0)	10778 (24.7)	0.01
Vaccination Status						
Encounter for herpes zoster vaccination	3884 (8.9)	169650 (8.2)	0.03	3884 (8.9)	3831 (8.8)	0.00
Laboratory data						
BMI, n (%)						
$\geq 25 (\text{kg/m}^2)$	8572 (19.6)	259197 (12.5)	0.20	8572 (19.6)	8576 (19.6)	0.00
C reactive protein, n (%)						
$\geq 3 (mg/L)$	3434 (7.9)	73956 (3.6)	0.19	3434 (7.9)	3169 (7.3)	0.02
Procalcitonin, n (%)						
$\geq 10 (ng/ml)$	10 (0.0)	146 (0.0)	0.01	10 (0.0)	10 (0.0)	0.00

Bold font represents a standardized difference was more than 0.1; In order to protect privacy of individuals, in the TriNetX research network, if the patient amount is less or equal to 10, results show the count as 10

<sup>a</sup> Propensity score matching was performed on age at index, sex, race, body mass index, lab data, status of comorbidities, lifestyle, socioeconomic issues, medical utilization status, vaccination for herpes zoster status.



Figure 2. Kaplan-Meier plot of the risk of herpes zoster.

#### Stratified analyses by gender and age groups

The analysis was further stratified by gender and age groups to investigate potential moderators of the observed association between TKR and HZ risk. Compared to the control cohort, the hazard ratio of HZ was significantly higher for both females and older adults in the TKR cohort. As detailed in **Table 2**. the hazard ratio for males was 1.097 (95% CI: 0.887-1.357), while the hazard ratio for females was 1.146 (95% CI: 1.001-1.311). The hazard ratio of HZ for patients aged 65 years or older was significantly higher than non-TKR population in the same age

subgroup (HR=1.195; 95% CI: 1.057-1.351). However, for people aged between 18-49 years old and 50-65 years old, the risk of HZ in TKR group was insignificant. In both age subgroups, female TKR patients presented statistically significant risk in developing HZ while comparing with non TKR female patients (50-64 years old, HR=1.543, 95% CI: 1.026-2.320; 65 years old above, HR=1.162, 95% CI: 1.008-1.339), whereas male TKR patients presented did not present significant risk in developing HZ while comparing with non TKR female patients (Table 3).

<b>TADIC 2.</b> Su autocation analysis of her pes zoster in total knee replacement patient	Table	<ol><li>Stratification</li></ol>	analysis of her	pes zoster in to	tal knee rep	placement patients
--	-------	----------------------------------	-----------------	------------------	--------------	--------------------

	Cases occurring new-onset herpes zoster		
Subgroups	Total knee replacement cohort	Control cohort	HR (95% CI) <sup>a,b</sup>
	(No. of event/ Total knee replacement patient	(No. of event/ non-total knee replacement	
	amount in each subgroup)	patient amount in each subgroup)	
Gender			
Male	181/16851	160/16851	1.097 (0.887,1.357)
Female	461/26721	392/26721	1.146 (1.001,1.311)
Age at index date			
18-49 years old <sup>c</sup>	≤ 10/373	≤ 10/373	0.463 (0.116,1.853)
50-64 years old	78/6149	62/6149	1.245 (0.892,1.737)
≥ 65 years old	592/38492	486/38492	1.187 (1.052,1.338)

<sup>a</sup> Propensity score matching was performed on age at index, sex, race, body mass index, lab data, status of comorbidities, lifestyle, socioeconomic issues, medical utilization status, vaccination for herpes zoster status.

<sup>b</sup> Follow-up time in all analyses in this table was set as 5-years, starting from 90 days after index date

c In order to protect privacy of individuals, in the TriNetX research network, if the patient amount is less or equal to 10, results show the count as 10

#### **Table 3.** Herpes zoster risk stratified by sex in different age subgroups.

	Cases occurring new-onset herpes zoster		
Subgroups	Total knee replacement cohort	Control cohort	HR (95% CI) <sup>a,b</sup>
	(No. of event/ Total knee replacement patient	(No. of event/ non-total knee replacement patient	
	amount in each subgroup)	amount in each subgroup)	
50-64 years old			
Male	19/2517	23/2517	0.829 (0.452,1.522)
Female	59/3590	38/3590	1.543 (1.026,2.320)
≥ 65 years old			
Male	165/14699	144/14699	1.111 (0.889,1.389)
Female	419/23559	352/23559	1.162 (1.008,1.339)

<sup>a</sup> Propensity score matching was performed on age at index, sex, race, body mass index, lab data, status of comorbidities, lifestyle, socioeconomic issues, medical utilization status, vaccination for herpes zoster status.

<sup>b</sup> Follow-up time in all analyses in this table was set as 5-years, starting from 90 days after index date

Outcomes	Study cohort, n (%)			Hazard ratio (95% CI)
	TKR patients	non-TKR patients		
Herpes zoster	646(1.48)	515(1.18)		1.223(1.089,1.373)
Secondary outcomes				
Zoster encephalitis	10(0.01)	10(0.01)	۰	1.909 (0.173,21.054)
Zoster with other nervous systemic involvement	139(0.32)	129(0.30)	<b>⊢</b>	1.042 (0.820,1.324)
Zoster ocular disease	42(0.10)	27(0.06)	•	1.493 (0.920,2.421)
Disseminated zoster	10(0.01)	10(0.01)		0.407 (0.105,1.572)
Zoster with other complications	51(0.12)	49(0.11)		1.001 (0.676,1.482)
Zoster without complications	550(1.26)	454(1.04)		1.173 (1.036,1.329)
				E

Figure 3. Risk of herpes zoster and secondary outcomes in people underwent total knee replacement. Legends: Data present here were the value of follow up from 90 days after index date to the respective following up years. Propensity score matching was performed on age at index, sex, race, body mass index, lab data, status of comorbidities, lifestyle, socioeconomic issues, medical utilization status, vaccination for herpes zoster status.

# Discussion

In this study, we investigated the association between TKR and the risk of HZ in OA patients. We found that TKR was associated with a higher risk of HZ compared to patients who did not undergo this procedure, and this association persisted across different follow-up periods up to 5 years and covariate-matching models. We also stratified different age and sex subgroups to discuss the potential role of the two covariates in the observed association.

The mechanisms behind the association between TKR and HZ are unclear, but they may involve multiple factors that impact the immune and nervous systems. HZ occurs when the varicella-zoster virus (VZV) reactivates, remaining dormant in the dorsal root ganglia following the initial infection[1]. Reactivation can be triggered by various factors, including immunosuppression, surgical stress, nerve injury, and exposure to VZV[19-22]. TKR is a major surgical intervention that can induce these risk factors, potentially leading to HZ development. First, TKR causes extensive tissue damage, blood loss, and inflammation, which may weaken the immune response and increase the susceptibility to HZ[23]. TKR also requires the use of perioperative medications, such as general anesthesia, opioids, blood transfusion, and immunosuppressive drugs[24, 25], which may further suppress cell-mediated immunity facilitate VZV reactivation. and Furthermore, TKR-induced mechanical joint damage and somatosensory alterations may contribute to neural dysregulation and subsequent VZV reactivation within the dorsal root ganglia[26-28]. Additionally, the peri-operative environment during TKR presents potential exposures to VZV from healthcare personnel, visitors, or co-patients, particularly those lacking prior varicella-zoster vaccination. Therefore, TKR may increase the risk of HZ through a combination of immunological and neurological factors.

We also observed that the effect of TKR on HZ risk was modified by sex and age, suggesting some OA patients were more likely to develop HZ after TKR than others. This finding is in line with previous studies that identified age and sex as independent risk factors for HZ, with females and older adults having higher rates and worse outcomes of HZ than males and younger adults[29]. Several possible mechanisms may explain the effect modification by sex and age. First, older adults may have impaired cell-mediated immunity and increased inflammation, which make them more susceptible to HZ after TKR[29, 30]. Second, older adults may have more comorbid conditions, such as diabetes, hypertension, and cardiovascular diseases, that compromise their immune function and predispose them to HZ[29]. Third, females and older adults may respond differently to the factors associated with TKR, such as surgical stress, anesthesia, pain management, and recovery. For example, female and elderly patients usually require higher doses of opioids for pain relief, which suppress their cellular immunity and may increase their viral load of VZV[29, 31, 32]. Furthermore, female and elderly patients tend to have slower recovery and rehabilitation after TKR, which prolongs their exposure to potential triggers of HZ, such as nerve injury, inflammation, or infection[33]. Additionally, sex-specific hormonal and genetic factors may also contribute to the increased HZ risk observed in females after TKR. Fluctuating levels of female sex hormones, including estrogens and progesterone, are known to modulate immune responses to pathogens such as VZV[34]. Hormonal changes during reproductive life events like puberty, menstrual cycling, pregnancy, and menopause could potentially reactivate latent VZV[35, 36]. Additionally, genetic polymorphisms linked to altered viral immunity and latency have been identified; some of these high-risk alleles may occur at higher frequency in women[37, 38]. Further research is needed to elucidate the effects of female sex hormones and genetic susceptibility on HZ pathogenesis after major surgery like TKR.

It is important to note that TKR patients are susceptible to various other types of infections as well. Periprosthetic joint infection (PJI) is one of the most serious complications following TKR, with an incidence rate of approximately 1-2%[39, 40]. PJI can be caused by a variety of pathogens, with Staphylococcus aureus and coagulase-negative staphylococci being the most common[41]. Other less frequent but significant infections include surgical site infections, which can be superficial or deep, and occur in about 0.5-1.5% of TKR patients[42]. Urinary tract infections are also relatively common, particularly in the immediate postoperative period, with rates ranging from 1.5-4% [43]. Additionally, patients may develop pneumonia, especially those with prolonged hospital stays or those requiring mechanical ventilation[42]. These various infections not only impact patient outcomes and quality of life but also contribute significantly to healthcare costs and resource utilization[39, 40]. The risk factors for these infections often overlap with those for HZ, including immunosuppression, advanced age, and comorbidities such as diabetes[41, 42]. Therefore, a comprehensive approach to infection prevention and management is crucial in the care of TKR patients.

Our study has several strengths. First, we used a large sample size in each cohort, increasing our findings' statistical power and precision. Second, we utilized propensity score matching methods that enabled us to bring about similar baseline characteristics between the TKR and the control group thereby reducing confounding bias in our study. Third, we did sensitivity analyses and demonstrated the robustness of our findings.

However, our study also has some limitations that should be acknowledged. First, as this was an observational study, causal relationships between TKR and HZ cannot be definitively determined. Second, we used administrative data, which may have some inaccuracies or incompleteness in diagnosing and coding HZ and other variables. Third, we did not have information on some potential confounders, such as smoking status, body mass index, and family history of HZ. Fourth, since this study utilizes a U.S. database, the findings may not be fully representative of the broader population, limiting generalizability to other countries or healthcare systems with different demographics or clinical practices. Future studies should address these limitations, explore these issues further, and include more diverse populations to enhance the generalizability of the results. Fifth, the difference in subtypes of total knee replacement could potentially cause difference in the observed TKR-HZ association. In the current study, total knee replacement was identified based on ICD-10-PCS codes. In this case, we were not able to clearly identify whether the surgery was primary or revision type. Sixth, only a small portion of patients can be followed for 15 years, and this could reduce statistical power to produce robust results in the 15-year follow-up sensitivity analysis.

Despite these limitations, our study provides evidence that OA patients who undergo TKR have a higher risk of developing HZ infection, especially if they are female or older. This finding has profound clinical implications, as HZ can cause severe pain and complications. Clinicians caring for TKR patients should vigilantly monitor for signs and symptoms of HZ, including pain, tingling, itching, or rash, and promptly diagnose and initiate treatment if HZ is suspected. Certain high-risk subgroups, such as female and elderly TKR patients, may warrant particularly close surveillance for HZ in the postoperative period. Patients should be aware of the risks and benefits of TKR, including the possible increased risk of HZ, and discuss their risk factors and preventive measures, such as antiviral drugs or vaccines, with their physicians. Future research should explore the mechanisms and outcomes of HZ after TKR and develop risk prediction models that

incorporate patient factors, such as age, gender, and comorbidities. This could help identify and prevent HZ in TKR patients and optimize prevention and treatment strategies.

In conclusion, this study demonstrated that TKR is associated with an increased risk of HZ, particularly for females and older adults. These findings highlight the importance of patient education regarding HZ risk after TKR, as well as the need for physicians to maintain a high index of suspicion for HZ in the post-TKR population. Further research is warranted to elucidate the mechanisms underlying the increased HZ incidence post-TKR and identify optimal preventive, diagnostic, and therapeutic strategies to mitigate HZ burden in these patients. Implementing targeted education, prevention, diagnosis, and management protocols may improve outcomes and reduce complications in TKR patients at risk for HZ reactivation.

# Supplementary Material

Supplementary tables. https://www.medsci.org/v21p2244s1.pdf

# Acknowledgements

#### Funding

This study was supported by research grants to Dr. Wen-Chieh Liao from the National Science and Technology Council (111-2320-B-005 -009 -MY3), Taiwan.

#### **Ethics statement**

The current study complied with the Declaration of Helsinki and was exempted of ethical approval by the Institutional Review Board of Tungs' Taichung MetroHarbor Hospital (IRB TTMHH No.:112207N).

#### Data availability statement

Data in this study were retrieved from TriNetX Research Network. All data available in the database were administrated by the TriNetX platform. Detailed information can be retrieved at the official website of the research network (https://trinetx.com). Upon appropriate requests, the analyzed datasets in this study could be provided by the authors. Datasets analyzed in the present study can be provided by the authors upon reasonable request.

#### Author contributions

All the authors involved in drafting or revising the article and approved of the submitted version.

Study conception and design: Li CP, Lo SW, Juang SE, Wu CL, Chang HC, Liao WC and Gau SY

Data acquisition: Chang HC and Gau SY

Data analysis and demonstration: Li CP, Lo SW, Chang HC, Liao WC and Gau SY

Original draft preparation: Li CP, Lo SW, Juang SE, Wu CL, Chang HC, Liao WC and Gau SY

# **Competing Interests**

The authors have declared that no competing interest exists.

## References

- Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clinic Proceedings. 2009; 84: 274-80.
- Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports. 2008; 57: 1-30.
- van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Human Vaccines & Immunotherapeutics. 2021; 17: 1714-32.
- Rosamilia LL. Herpes zoster presentation, management, and prevention: a modern case-based review. American Journal of Clinical Dermatology. 2020; 21: 97-107.
- García-González AI, Rosas-Carrasco O. Herpes zoster and post-herpetic neuralgia in the elderly: Particularities in prevention, diagnosis, and treatment. Gac Med Mex. 2017; 153: 92-101.
- Latheef EA, Pavithran K. Herpes zoster: a clinical study in 205 patients. Indian journal of dermatology. 2011; 56: 529.
- Weller TH. Varicella and Herpes Zoster: (Second of Two Parts). New England Journal of Medicine. 1983; 309: 1434-40.
- Furuta Y, Ohtani F, Fukuda S, Inuyama Y, Nagashima K. Reactivation of varicella-zoster virus in delayed facial palsy after dental treatment and orofacial surgery. Journal of medical virology. 2000; 62: 42-5.
- Mansour N, Kaliaperumal C, Choudhari KA. Facial herpes zoster infection precipitated by surgical manipulation of the trigeminal nerve during exploration of the posterior fossa: a case report. Journal of Medical Case Reports. 2009; 3: 1-3.
- Muesse JL, Blackmon SH, Harris RL, Kim MP. Acute shingles after resection of thoracic schwannoma. Texas Heart Institute Journal. 2012; 39: 265.
- Neuprez A, Neuprez AH, Kaux J-F, Kurth W, Daniel C, Thirion T, et al. Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. Clinical rheumatology. 2020; 39: 861-71.
- Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. The Journal of Bone and Joint Surgery American volume. 2012; 94: 201.
- Wei Z, Weng X. Case report: Be alert to herpes zoster after total knee arthroplasty. Frontiers in Surgery. 2023; 10: 1042482.
- Jain M, Tripathy PR, Mohanty CR. Case Report: Post-total knee arthroplasty herpes zoster activation. BMJ Case Reports. 2019; 12.
- Chang HC, Lu HY, Guo YC, Lin CY, Chen SJ, Gau SY. Depression risk in chronic tonsillitis patients underwent tonsillectomy: a global federated health network analysis. Int J Med Sci. 2024; 21: 949-57.
- Gau SY, Guo YC, Lu HY, Lin CY, Lee CY, Tsai RY, et al. Hidradenitis suppurativa as a potential risk factor of periodontitis: a multi-center, propensity-score-matched cohort study. Int J Med Sci. 2024; 21: 874-81.
- Chang H-C, Lin C-Y, Guo Y-C, Lu H-Y, Lee C-Y, Wu M-C, et al. Association between hidradenitis suppurativa and atopic diseases: a multi-center, propensity-score-matched cohort study. International Journal of Medical Sciences. 2024; 21: 299-305.
- Chang H-C, Wu C-L, Chiu T-M, Liao W-C, Gau S-Y. Risk of osteoarthritis in patients with hidradenitis suppurativa: a global federated health network analysis. Frontiers in Immunology. 2023; 14: 1285560.
- Kennedy PGE, Gershon AA. Clinical Features of Varicella-Zoster Virus Infection. Viruses. 2018; 10: 609.
- Arvin AM. Immune responses to varicella-zoster virus. Infect Dis Clin North Am. 1996; 10: 529-70.
- Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant. 2000; 6: 44-9.
- Eckermann J, Meyer JE, Guenzel T. Etiology and therapy of delayed facial paralysis after middle ear surgery. Eur Arch Otorhinolaryngol. 2020; 277: 965-74.
- Li CY, Ng Cheong Chung KJ, Ali OME, Chung NDH, Li CH. Literature review of the causes of pain following total knee replacement surgery: prosthesis, inflammation and arthrofibrosis. EFORT Open Rev. 2020; 5: 534-43.

- Hansen CW, Carlino EK, Saunee LA, Dasa V, Bhandutia AK. Modern Perioperative Pain Management Strategies to Minimize Opioids after Total Knee Arthroplasty. Orthop Clin North Am. 2023; 54: 359-68.
- Pepper AM, Mercuri JJ, Behery OA, Vigdorchik JM. Total Hip and Knee Arthroplasty Perioperative Pain Management: What Should Be in the Cocktail. JBJS Rev. 2018; 6: e5.
- Nogalo Ć, Meena A, Abermann E, Fink C. Complications and downsides of the robotic total knee arthroplasty: a systematic review. Knee Surg Sports Traumatol Arthrosc. 2023; 31: 736-50.
- Zerboni L, Arvin A. Neuronal Subtype and Satellite Cell Tropism Are Determinants of Varicella-Zoster Virus Virulence in Human Dorsal Root Ganglia Xenografts In Vivo. PLoS Pathog. 2015; 11: e1004989.
- Reichelt M, Zerboni L, Arvin AM. Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol. 2008; 82: 3971-83.
- Kawai K, Yawn BP. Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2017; 92: 1806-21.
- Yoshikawa TT, Schmader K. Herpes zoster in older adults. Clinical Infectious Diseases. 2001; 32: 1481-6.
- Nasser SA, Afify EA. Sex differences in pain and opioid mediated antinociception: Modulatory role of gonadal hormones. Life sciences. 2019; 237: 116926.
- Kaye AD, Baluch A, Scott JT. Pain management in the elderly population: a review. Ochsner Journal. 2010; 10: 179-87.
- Vincent KR, Vincent HK, Lee LW, Alfano AP. Outcomes in total knee arthroplasty patients after inpatient rehabilitation: influence of age and gender. American journal of physical medicine & rehabilitation. 2006; 85: 482-9.
- Butts CL, Sternberg EM. Neuroendocrine factors alter host defense by modulating immune function. Cell Immunol. 2008; 252: 7-15.
- Laemmle L, Goldstein RS, Kinchington PR. Modeling varicella zoster virus persistence and reactivation-closer to resolving a perplexing persistent state. Frontiers in microbiology. 2019; 10: 1634.
- Gerada C, Campbell TM, Kennedy JJ, McSharry BP, Steain M, Slobedman B, et al. Manipulation of the innate immune response by varicella zoster virus. Frontiers in immunology. 2020; 11: 1.
- Yu X, Lophatananon A, Mekli K, Muir KR, Guo H. Exploring the causal role of the immune response to varicella-zoster virus on multiple traits: a phenome-wide Mendelian randomization study. BMC Med. 2023; 21: 143.
- Gerada C, Campbell TM, Kennedy JJ, McSharry BP, Steain M, Slobedman B, et al. Manipulation of the Innate Immune Response by Varicella Zoster Virus. Front Immunol. 2020; 11: 1.
- 39. Zahar A, Sarungi M. Diagnosis and management of the infected total knee replacement: a practical surgical guide. J Exp Orthop. 2021; 8: 14.
- Weinstein EJ, Stephens-Shields AJ, Newcomb CW, Silibovsky R, Nelson CL, O'Donnell JA, et al. Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty. JAMA Netw Open. 2023; 6: e2340457.
- Chun KC, Kim KM, Chun CH. Infection following total knee arthroplasty. Knee Surg Relat Res. 2013; 25: 93-9.
- de Carvalho Junior LH, Temponi EF, Badet R. Infection after total knee replacement: diagnosis and treatment. Rev Bras Ortop. 2013; 48: 389-96.
- Nguyen AQ, Foy MP, Sood A, Gonzalez MH. Preoperative risk factors for postoperative urinary tract infection after primary total hip and knee arthroplasties. The Journal of Arthroplasty. 2021; 36: 734-8.